Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: RockDoc who wrote (2291)	4/6/1999 3:34:00 PM
From: Joe	Read Replies (1) \| Respond to of 4140

Rock, I will be going to ASCRS and will talk with them. Also will attend any presentation of their data. Refractec has been around for quite a while. This is not new information to anyone that had done adequate DD for any major investment in SNRS. Before I would worry about a $40K competitor, I would worry about KERA. Assuming the ring works for hyperopia, my guess is they will have approval long before Refractec. But remember that both KERA and Refractec are invasive. I don't think anyone owning VISX is worried much about KERA (unless you owned 1/2 million shares, then you worry about everything, including the IRS.) Joe